The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial
Abstract
IMPORTANCE: Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients with remitted first-episode psychosis (FEP) showed higher relapse rates but no other disadvantages compared with maintenance treatment; however, long-term effects on recovery have not been studied before. OBJECTIVE: To compare rates of recovery in patients with remitted FEP after 7 years of follow-up of a dose reduction/discontinuation (DR) vs maintenance treatment (MT) trial. DESIGN: Seven-year follow-up of a 2-year open randomized clinical trial comparing MT and DR. SETTING: One hundred twenty-eight patients participating in the original trial were recruited from 257 patients with FEP referred from October 2001 to December 2002 to 7 mental health care services in a 3.2 million-population catchment area. Of these, 111 patients refused to participate and 18 patients did not experience remission. PARTICIPANTS After 7 years, 103 patients (80.5%) of 128 patients who were included in the original trial were located and consented to follow-up assessment. INTERVENTION: After 6 months of remission, patients were randomly assigned to DR strategy or MT for 18 months. After the trial, treatment was at the discretion of the clinician. MAIN OUTCOMES AND MEASURES: Primary outcome was rate of recovery, defined as meeting the criteria of symptomatic and functional remission. Determinants of recovery were examined using logistic regression analysis; the treatment strategy (MT or DR) was controlled for baseline parameters. RESULTS: The DR patients experienced twice the recovery rate of the MT patients (40.4% vs 17.6%). Logistic regression showed an odds ratio of 3.49 (P = .01). Better DR recovery rates were related to higher functional remission rates in the DR group but were not related to symptomatic remission rates. CONCLUSIONS AND RELEVANCE: Dose reduction/discontinuation of antipsychotics during the early stages of remitted FEP shows superior long-term recovery rates compared with the rates achieved with MT. To our knowledge, this is the first study showing long-term gains of an early-course DR strategy in patients with remitted FEP. Additional studies are necessary before these results are incorporated into general practice. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16228411.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“That is, relapses are not distributed evenly across time but tend to occur predominantly around the point of drug cessation.”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
In the citing paper
“It appears that relapse rates are raised in the discontinuation group for 1–3 years following a switch to placebo, before converging with relapse rates of medicated patients thereafter.3,56–59”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
In the citing paper
“one found 43% of the original cohort of patients relapsed in the first year, 21.5% in the second year, and just 3.7% a year in each of the 5 years following57,61”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,350
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
Lewis, D. A., Curley, A. A., Glausier, J. R., & Volk, D. W. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.10.004 · Cited by 1,071
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434
Wunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234
Self-citationGrace, A. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.011 · Cited by 225
Cited by
Sorted by citations
Items 501–567 of 567
Computer-based Approaches to Cognitive Enhancement
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.007
Cognition and Its Impairment in Schizophrenia and Related Psychotic Disorders
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.003
Who Responds Best? Predictors and Moderators of Cognitive Enhancement
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.010
Individual and Group Approaches to Cognitive Enhancement
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.008
Psychofarmaca: pleidooi voor een voorzichtig beleid bij vroege psychose
Bouwel, L. V. (2021) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.77.21.098
Is change over time in psychotic symptoms related to social functioning?
Kwakernaak, S., GROUP Investigators, Cahn, W., & Janssen, R. T. J. M. (2021) · International Journal of Social Psychiatry · doi:10.1177/00207640211039248
Research in Cognitive Enhancement
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.013
Tettamanti, M., Bessero, S., & Curtis, L. (2021) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2021.09.020
Tani, H., Tomita, M., Suzuki, T., Mimura, M., & Uchida, H. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.4.773
From the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic Era
Fountoulakis, K. (2021) · Psychiatry · doi:10.1007/978-3-030-86541-2_11 · Cited by 1
Approaches to Assessment and Monitoring Treatment Response
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.012
Choosing the Right Treatment for the Right Patient
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.011
Getting Ready for Cognitive Enhancement
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.006
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.005
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.014
Dame, T. W. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.001
(2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.015
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.002
Schizophrenie, schizotype und wahnhafte Störungen (F2)
Nickl‐Jockschat, T., & Schneider, F. W. (2016) · Springer eBooks · doi:10.1007/978-3-662-50345-4_21
Bibliography: Psychopharmacology: Evidence and Treatments
(2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.184
Hell, D., & Schüpbach, D. (2016) · Springer eBooks · doi:10.1007/978-3-662-48932-1_5
Benkert, O. (2014) · Springer eBooks · doi:10.1007/978-3-642-54769-0_3
(2017) · Wiley eBooks · doi:10.1002/9781119183839.refs
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.016
Psychosis, antipsychotics and premature mortality: The elephant in the room
Horwood, F. (2016) · Clinical Psychology Forum · doi:10.53841/bpscpf.2016.1.284.11
Predicting psychotic relapse following paliperidone discontinuation
Suzuki, T. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00031-7
About Hobbits, Jedi, Goddesses and Magical Energies: Clinical Cases from ART
Zúñiga, R., Díaz-Garrido, J. A., Laffite, H., & Cejas-Méndez, M. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-27003-1_18
Neuroleptics Do Much More Harm Than Good and Should Not Be Used
Gøtzsche, P. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-27003-1_4
Rethinking Antipsychotics: Evidence-Based Medicine Calls for a Dramatic Change in Their Use
Whitaker, R. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-27003-1_3
Advocating for Integrated Therapy in the Social Environment to Treat Schizophrenia Problems
Aguayo, L. V., Valenzuela-Hernández, M., de Miguel, S. O., Ruiz-Sánchez, J. J., & Díaz-Garrido, J. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-27003-1_5 · Cited by 1
Weinmann, S. (2023) · Psychiatrische Praxis · doi:10.1055/a-1952-1910
Hasler, F. (2023) · transcript Verlag eBooks · doi:10.14361/9783839445716 · Cited by 2
Multi-nutrients as Adjunctive Treatment for Bipolar Disorder: A randomized-controlled trialPreprint
Mehl‐Madrona, L., & McFarlane, P. S. (2023) · medRxiv · doi:10.1101/2023.06.23.23291534
Early Intervention Across Mental Health Services
Brown, E., Stainton, A., Chanen, A. M., Davey, C. G., Bedi, G., & McGorry, P. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_171-1
Antipsychotische Dosisreduktion führt nicht zu besserem sozialen Funktionsniveau
Hasan, A. (2023) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-023-3485-3
Lincoln, T. M. (2015) · Wiley eBooks · doi:10.1002/9781394259229.ch17
Paradigm Shift to Promote a Revolution of Treatment of Schizophrenia to Achieve Recovery
Keim, W. (2023) · Medical Research Archives · doi:10.18103/mra.v11i12.4866 · Cited by 1
Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks
Lawrence, R. E., & Appelbaum, P. S. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.01.018
Foreman, D. M. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.230137
Insights in social psychiatry and psychiatric rehabilitation: 2022
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4568-3
Paudel, S., Lim, C., & Freudenreich, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00050-3
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Early Intervention Across Mental Health Services
Brown, E., Stainton, A., Chanen, A. M., Davey, C. G., Bedi, G., & McGorry, P. D. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_171
Paudel, S., Lim, C., & Freudenreich, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00009-0
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
Krivoy, A., Tiihonen, J., Nissan, J., Dotan, A., Arnheim, D., Menkes-Caspi, N., Taub, S., Tuppurainen, H., Mittendorfer‐Rutz, E., Davidson, M., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf011
Yen, K., Hsieh, M. H., Chien, Y., Liu, C., Lin, Y., Hwang, T., Liu, C.-I., & Liu, C.-C. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104534
Arango, C., Baeza, I., García‐Rizo, C., Crespo‐Facorro, B., Lahera, G., Vieta, E., Becker, F., Dwyer, G., Bourke, S., Gibson, A. E. J., et al. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s494721
O’Neill, J. R., Wilson, C., Horowitz, M. A., McLean, S. L., Faisal, M., Dixon, M., Couchman, L., Lawlor, K., & Crowther, G. J. E. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10831 · Cited by 1
Ruiz‐Pérez, G., Ulrich, N., Bettin, J., Lippert, J., Koch, T., & von Peter, S. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01922-7
Huber, A., Vukmirović, J., Haydarlou, R., & Jan Treur, A. (2025) · Cognitive Systems Research · doi:10.1016/j.cogsys.2025.101423
Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19366114
Negative Symptoms in Schizophrenia: The Role of Pharmacotherapy
Bitter, I., & Czobor, P. (2025) · Comprehensive approach to psychiatry · doi:10.1007/978-3-032-06209-3_6
Interpretation of the HAMLETT Study
Wunderink, L. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.4444
Osugo, M., & Howes, O. D. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag017
Kishi, T., Citrome, L., Sakuma, K., Hatano, M., & Iwata, N. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112828
Challenges in Understanding and Management of Relapse in Schizophrenia
Pai, N. B., & Vella, S. (2026) · Journal of Psychiatry Spectrum · doi:10.4103/jopsys.jopsys_76_25
Moncrieff, J., Long, M., Priebe, S., Akther-Robertson, J., Barnes, T. R. E., Bray, G., Cooper, R. E., Crellin, N. E., Darton, K., Freemantle, N., et al. (2025) · Programme Grants for Applied Research · doi:10.3310/gjjm0506
Medications for Psychosis in People with Schizophrenia
Faizi, A., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009587747.011
Do Antipsychotics Work in People with Schizophrenia?
Correll, C. U. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009587747.008
The evidence on the deprescribing of antipsychotic medication in people with psychotic disorders
Li, J., Large, M. M. B., & Nielssen, O. B. (2026) · Australasian Psychiatry · doi:10.1177/10398562261442181
Berna, F., Horowitz, M., Javelot, H., Meyer, N., & Foucher, J. R. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-117593
Guided tapering of antipsychotics in patients with Schizophrenia: Relapse-status and cognition
Nøstdal, A., Nielsen, M. Ø., Fagerlund, B., Nielsen, J. N., & Lemvigh, C. K. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.07.013
Deprescribing in Special Populations: Optimizing Medication Use Across Complex Patient Groups
Zidan, A., Habib, S., Hamad, A., Hadi, M. A., & Awaisu, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00046-2
Nosologie und Epidemiologie psychischer Störungen
Hengartner, M. P. (2026) · Angewandte Psychologie Kompakt · doi:10.1007/978-3-662-72845-1_3
Allott, K., Chopra, S., O'Donoghue, B. N., Nelson, B., Ratheesh, A., Álvarez‐Jiménez, M., Fornito, A., Harrigan, S., Thompson, A. D., Wood, S. J., et al. (2026) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674261490058
Metadata
- Authors
- Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J.
- Affiliations
- University Medical Center Groningen (NL)
- Corresponding author
- Wunderink, Lex
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2013-09-01
- Volume
- 70
- Issue
- 9
- Pages
- 913
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2125616168
- Cited by
- 567
- References
- 24
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 31 · 2023: 39 · 2022: 37 · 2021: 47 · 2020: 42 · 2019: 71 · 2018: 59 · 2017: 43 · 2016: 65 · 2015: 42 · 2014: 36 · 2013: 8
- FWCI
- 35.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Keywords
- first-episode psychosis, remission, antipsychotic dose reduction, antipsychotic discontinuation, long-term antipsychotic treatment, long-term recovery, functional remission, symptom remission, relapse
- MeSH terms
- Adult, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Psychotic Disorders, Recurrence, Remission Induction, Antipsychotic Agents, Treatment Outcome, Age of Onset, Young Adult, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review